Our providers help determine which weight loss prescription best fits your lifestyle and insurance coverage
Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N et al
In a 4-week controlled trial of VYVANSE in pediatric patients ages 13 to 17 years, mean weight loss from baseline to endpoint was -2.7, -4.3, and -4.8 lbs., respectively, for patients receiving 30 mg, 50 mg, and 70 mg of VYVANSE, compared to a 2.0 pound weight gain for patients receiving placebo
Patients and clinicians should remain alert to symptoms such as a new neck lump, hoarseness, or difficulty swallowing, and seek prompt medical assessment if these occur